The REMAR (Rhein-Main-Registry) real-world study: prospective evaluation of the 21-gene breast recurrence score® assay in addition to Ki-67 for adjuvant treatment decisions in early-stage breast cancer
Breast Cancer Research and Treatment · 2024
DOI: 10.1007/s10549-024-07390-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2024. Verfasst von Christian Jackisch und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Obstetrics, Sana Klinikum Offenbach GmbH, Offenbach, Germany. c.jackisch@kem-med.com. Hauptthemen laut MEDLINE: Breast Neoplasms, Ki-67 Antigen, Neoplasm Recurrence, Local, Biomarkers, Tumor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Exact Sciences.
Abstract (Originalsprache)
Purpose
Ki-67 is recommended by international/national guidelines for risk stratification in early breast cancer (EBC), particularly for defining “intermediate risk,” despite inter-laboratory/inter-observer variability and cutoff uncertainty. We investigated Ki-67 (> 10%– < 40%, determined locally) as a prognostic marker for intermediate/high risk in EBC, pN0-1 patients.
Methods
This prospective, non-interventional, real-world study included females ≥ 18 years, with pN0/pN1mi/pN1, HR+ , HER2-negative EBC, and locally determined Ki-67 ranging 10%–40%. The primary outcome was changes in treatment recommendations after disclosing the Oncotype DX Breast Recurrence Score ® (RS) assay result.
Results
The analysis included 567 patients (median age, 57 [range, 29–83] years; 70%/1%/29%/ with pN0/pN1mi/pN1 disease; 81% and 19% with RS results 0–25 and 26–100, respectively). The correlations between local and central Ki-67, local Ki-67, and the RS, and central Ki-67 and the RS results were weak ( r = 0.35, r = 0.3, and r = 0.46, respectively), and discrepancies were noted in both directions (e.g., local Ki-67 was lower or higher than central Ki-67). After disclosing the RS, treatment recommendations changed for 190 patients (34%). Changes were observed in pN0 and pN1mi/pN1 patients and in patients with centrally determined Ki-67 ≤ 10% and > 10%. Treatment changes were aligned with RS results (adding chemotherapy for patients with higher RS results, omitting it for lower RS results), and their net result was 8% reduction in adjuvant chemotherapy use (from 32% pre-RS results to 24% post-RS results).
Conclusion
The Oncotype DX ® assay is a tool for individualizing treatments that adds to classic treatment decision factors. The RS result and Ki-67 are not interchangeable, and Ki-67, as well as nodal status, should not be used as gatekeepers for testing eligibility, to avoid under and overtreatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology and Obstetrics, Sana Klinikum Offenbach GmbH, Offenbach, Germany. c.jackisch@kem-med.com.
- OncoNet Rhein Main e. v., Frankfurt, Germany. c.jackisch@kem-med.com.
- KEM, Evang. Kliniken Essen-Mitte gGmbH, Henricistr. 92, 45136, Essen, Germany. c.jackisch@kem-med.com.
- Department of Palliative Medicine, Agaplesion Markus Hospital, Frankfurt, Germany.
- Optipath Frankfurt MVZ Pathology, Frankfurt, Germany.
- Department of Gynecology and Obstetrics, Sana Klinikum Offenbach GmbH, Offenbach, Germany.
Förderung
- Exact Sciences
Zitieren
APA
Jackisch, C., Anastasiadou, L., Aulmann, S., Argyriadis, A., Möbus, V., Solbach, C., Baier, P., Giesecke, D., Ackermann, S., Schulmeyer, E., Gabriel, B., Mosch, D., Buchen, S., Krapfl, E., Hurst, U., Vescia, M., Tesch, H., & Thill, M. (2024). The REMAR (Rhein-Main-Registry) real-world study: prospective evaluation of the 21-gene breast recurrence score® assay in addition to Ki-67 for adjuvant treatment decisions in early-stage breast cancer. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07390-y
Vancouver
Jackisch C, Anastasiadou L, Aulmann S, Argyriadis A, Möbus V, Solbach C, et al. The REMAR (Rhein-Main-Registry) real-world study: prospective evaluation of the 21-gene breast recurrence score® assay in addition to Ki-67 for adjuvant treatment decisions in early-stage breast cancer. Breast Cancer Research and Treatment. 2024. doi:10.1007/s10549-024-07390-y
BibTeX
@article{Jackisch2024,
author = {Jackisch, Christian and Anastasiadou, Louiza and Aulmann, Sebastian and Argyriadis, Athanasios and Möbus, Volker and Solbach, Christine and Baier, Peter and Giesecke, Dagmar and Ackermann, Sven and Schulmeyer, Elke and Gabriel, Boris and Mosch, Dietrich and Buchen, Stephanie and Krapfl, Eckart and Hurst, Ursula and Vescia, Mario and Tesch, Hans and Thill, Marc},
title = {The REMAR (Rhein-Main-Registry) real-world study: prospective evaluation of the 21-gene breast recurrence score® assay in addition to Ki-67 for adjuvant treatment decisions in early-stage breast cancer},
journal = {Breast Cancer Research and Treatment},
year = {2024},
doi = {10.1007/s10549-024-07390-y}
}
EUVIMED